Pembrolizumab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 Jun 2022: Trial registered, NCT05420948
  2. 17 Oct 2022: Trial started, NCT05420948
  3. 18 Nov 2023: Trial registered, NCT06137378
  4. 17 Apr 2024: Trial started, NCT06137378

The trials

NCT05420948: A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

State
Under way
Phase
Phase 2
People
30 planned
Started
17 Oct 2022
Primary completion
1 Dec 2026
Arms
Group 1: Participants Who Receive Pembrolizumab (Alone)
Results
None posted
  1. 15 Jun 2022: Trial registered
  2. 17 Oct 2022: Trial started

NCT06137378: European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

State
Under way
Phase
Phase 2
People
140 planned
Started
17 Apr 2024
Primary completion
Dec 2028
Arms
B - KEYTRUDA®
Results
None posted
  1. 18 Nov 2023: Trial registered
  2. 17 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Keytruda, Keytruda qlex component pembrolizumab, Pembrolizumab 200 mg, Pembrolizumab Injection [Keytruda], Pembrolizumab SC.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.